Search

Your search keyword '"Motyl, Mary R."' showing total 222 results
Start Over Author "Motyl, Mary R."
222 results on '"Motyl, Mary R."'

16. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21

Author

Karlowsky, James A, primary, Lob, Sibylle H, additional, Hawser, Stephen P, additional, Kothari, Nimmi, additional, Siddiqui, Fakhar, additional, Alekseeva, Irina, additional, DeRyke, C Andrew, additional, Young, Katherine, additional, Motyl, Mary R, additional, and Sahm, Daniel F, additional

Published
2023
Full Text
View/download PDF

17. New Antimicrobial Agents... but No Susceptibility Tests!

Author

Ambler, Jane E., Krause, Kevin M., Steenbergen, Judith N., Scangarella-Oman, Nicole E., Miller, Linda A., Bhagwat, Sachin S., Serio, Alisa W., Chesnel, Laurent, Mahoney, Nicole M., Motyl, Mary R., Critchley, Ian A., Iaconis, Joseph P., Stone, Gregory G., Alder, Jeff, Xerri, Luigi, McCurdy, Sandra P., van Veenhuyzen, David F., Grossman, Trudy, Echols, Roger M., Williams, Gregory, and Bradford, Patricia A.

Published
2016
Full Text
View/download PDF

25. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20

Author

Karlowsky, James A, primary, Lob, Sibylle H, additional, Akrich, Brune, additional, DeRyke, C Andrew, additional, Siddiqui, Fakhar, additional, Young, Katherine, additional, Motyl, Mary R, additional, Hawser, Stephen P, additional, and Sahm, Daniel F, additional

Published
2022
Full Text
View/download PDF

26. Global Escherichia coli sequence type 131 clade with [bla.sub.CTX-M-27] gene

Author

Matsumura, Yasufumi, Pitout, Johann D.D., Gomi, Ryota, Matsuda, Tomonari, Noguchi, Taro, Yamamoto, Masaki, Peirano, Gisele, DeVinney, Rebekah, Bradford, Patricia A., Motyl, Mary R., Tanaka, Michio, Nagao, Miki, Takakura, Shunji, and Ichiyama, Satoshi

Subjects
Genes -- Analysis, DNA sequencing -- Analysis, Beta lactamases -- Analysis, Genomes -- Analysis, Genomics -- Analysis, Escherichia coli -- Analysis, Health
Abstract

The global increase in resistance to the third-generation cephalosporins and fluoroquinolones among extraintestinal pathogenic Escherichia coli (ExPEC) is a public health concern because of the importance of these drugs in [...]

Published
2016
Full Text
View/download PDF

27. Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosaand the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021

Author

Karlowsky, James A., Wise, Mark G., Hsieh, Tai-Chin, Lu, Hung-Chi, Chen, Wei-Ting, Cheng, Ming-Huei, Siddiqui, Fakhar, Young, Katherine, Motyl, Mary R., and Sahm, Daniel F.

Abstract

•CRPA in Taiwan increased from 12% in 2012–2015 to 19-23% in 2018–2021.•Only 2.1% of Taiwanese CRPA examined carried carbapenemase genes.•The most common carbapenemase among the CRPA was VIM (56%).•97.0% of all P. aeruginosaisolates tested from 2016 to 2021 were C/T susceptible.•91.3% of CRPA isolates tested from 2016 to 2021 were C/T susceptible.

Published
2023
Full Text
View/download PDF

28. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

Author

Karlowsky, James A., Lob, Sibylle H., DeRyke, C. Andrew, Hilbert, David W., Wong, Michael T., Young, Katherine, Siddiqui, Fakhar, Motyl, Mary R., and Sahm, Daniel F.

Subjects
Susceptibility
Abstract

Ceftolozane-tazobactam (C/T), imipenem-relebactam (IMR), and ceftazidime-avibactam (CZA) were tested against 2,531 P. aeruginosa strains isolated from patients in the United States from 2018 to 2020 as part of the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance program. MICs were determined by CLSI broth microdilution and interpreted using CLSI M100 (2021) breakpoints. Imipenem-, IMR-, or C/T-nonsusceptible isolates were screened for β-lactamase genes: 96.4% of all isolates and ≥70% of multidrug-resistant (MDR), pan-β-lactam-nonsusceptible, and difficult-to-treat resistance (DTR) isolates were C/T-susceptible; 52.2% of C/T-nonsusceptible isolates remained susceptible to IMR compared to 38.9% for CZA; and 1.7% of isolates tested were nonsusceptible to both C/T and IMR versus 2.2% of isolates with a C/T-nonsusceptible and CZA-resistant phenotype (a difference of 12 isolates). C/T and IMR modal MICs for pan-β-lactam-nonsusceptible isolates remained at or below their respective susceptible MIC breakpoints from 2018 to 2020, while the modal MIC for CZA increased 2-fold from 2018 to 2019 and exceeded the CZA-susceptible MIC breakpoint in both 2019 and 2020. Only six of 802 molecularly characterized isolates carried a metallo-β-lactamase, and two isolates carried a GES carbapenemase. Most P. aeruginosa isolates were C/T-susceptible, including many with MDR, pan-β-lactam-nonsusceptible, DTR, CZA-resistant, and IMR-nonsusceptible phenotypes. While C/T was the most active antipseudomonal agent, IMR demonstrated greater activity than CZA against isolates nonsusceptible to C/T.

Published
2022

29. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

Author

Karlowsky, James A., primary, Lob, Sibylle H., additional, DeRyke, C. Andrew, additional, Hilbert, David W., additional, Wong, Michael T., additional, Young, Katherine, additional, Siddiqui, Fakhar, additional, Motyl, Mary R., additional, and Sahm, Daniel F., additional

Published
2022
Full Text
View/download PDF

30. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017–2019

Author

Karlowsky, James A., primary, Lob, Sibylle H., additional, Khan, Aaron, additional, Chen, Wei-Ting, additional, Woo, Patrick C. Y., additional, Seto, Wing Hong, additional, Ip, Margaret, additional, Leung, Stanley, additional, Wong, Queenie W.-L., additional, Chau, Rene W. Y., additional, DeRyke, C. Andrew, additional, Young, Katherine, additional, Motyl, Mary R., additional, and Sahm, Daniel F., additional

Published
2022
Full Text
View/download PDF

37. Additional file 3 of Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Author

Karlowsky, James A., Lob, Sibylle H., Young, Katherine, Motyl, Mary R., and Sahm, Daniel F.

Abstract

Additional file 3: Fig. S1. Species distribution of 3717 isolates of Gram-negative bacilli collected from patients with lower respiratory tract infections – SMART 2018–2019, United States

Published
2021
Full Text
View/download PDF

38. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Maertens, Johan A, Rahav, Galia, Lee, Dong-Gun, Ponce-de-León, Alfredo, Ramírez Sánchez, Isabel Cristina, Klimko, Nikolay, Sonet, Anne, Haider, Shariq, Diego Vélez, Juan, Raad, Issam, Koh, Liang-Piu, Karthaus, Meinolf, Zhou, Jianying, Ben-Ami, Ronen, Motyl, Mary R, Han, Seongah, Grandhi, Anjana, Waskin, Hetty, study investigators, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Maertens, Johan A, Rahav, Galia, Lee, Dong-Gun, Ponce-de-León, Alfredo, Ramírez Sánchez, Isabel Cristina, Klimko, Nikolay, Sonet, Anne, Haider, Shariq, Diego Vélez, Juan, Raad, Issam, Koh, Liang-Piu, Karthaus, Meinolf, Zhou, Jianying, Ben-Ami, Ronen, Motyl, Mary R, Han, Seongah, Grandhi, Anjana, Waskin, Hetty, and study investigators

Abstract

Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. We did a randomised, prospective, double-blind, double-dummy, controlled trial comparing posaconazole (intravenous or oral posaconazole 300 mg twice on day 1, followed by 300 mg once a day for days 2-84) with voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2-84) for 12 weeks or less in the primary treatment of invasive aspergillosis. Participants were from 91 study sites in 26 countries, were aged 13 years or older, weighed at least 40 kg, and met criteria for proven, probable, or possible fungal disease. Participants were randomly assigned (1:1) via a computer-generated randomisation schedule with stratification by risk status. The primary endpoint was cumulative all-cause mortality up until day 42 in the intention-to-treat (ITT) population (defined as randomly assigned participants who received ≥1 dose of study drug), with a 10% non-inferiority margin. The ITT population was also evaluated for safety. This study is registered with ClinicalTrials.gov, NCT01782131, and EudraCT, 2011-003938-14. Between Oct 25, 2013, and Sept 10, 2019, of 653 individuals assessed for eligibility, 575 ITT participants were randomly assigned and received one or more doses of study drug (n=288 [50%] posaconazole, n=287 [50%] voriconazole). Mortality up until day 42 was 15% (44 of 288) in the posaconazole group and 21% (59 of 287) in the voriconazole group (treatment difference -5·3% [95% CI -11·6 to 1·0]; p<0·0001). Mortality up until day 42 in the full-analysis-set subpopulation (ITT participants with proven or probable invasive aspergillosis) supp

Published
2021

41. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Author

Maertens, Johan A, primary, Rahav, Galia, additional, Lee, Dong-Gun, additional, Ponce-de-León, Alfredo, additional, Ramírez Sánchez, Isabel Cristina, additional, Klimko, Nikolay, additional, Sonet, Anne, additional, Haider, Shariq, additional, Diego Vélez, Juan, additional, Raad, Issam, additional, Koh, Liang-Piu, additional, Karthaus, Meinolf, additional, Zhou, Jianying, additional, Ben-Ami, Ronen, additional, Motyl, Mary R, additional, Han, Seongah, additional, Grandhi, Anjana, additional, and Waskin, Hetty, additional

Published
2021
Full Text
View/download PDF

44. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes—Study for Monitoring Antimicrobial Resistance Trends, United States 2015–2017

Author

Karlowsky, James A, primary, Lob, Sibylle H, additional, Raddatz, Janet, additional, DePestel, Daryl D, additional, Young, Katherine, additional, Motyl, Mary R, additional, and Sahm, Daniel F, additional

Published
2020
Full Text
View/download PDF

47. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes—Study for Monitoring Antimicrobial Resistance Trends, United States 2015–2017

Author

Karlowsky, James A, Lob, Sibylle H, Raddatz, Janet, DePestel, Daryl D, Young, Katherine, Motyl, Mary R, and Sahm, Daniel F

Subjects
IN vitro studies, HOSPITALS, INTENSIVE care units, BETA lactam antibiotics, GRAM-negative bacteria, FLUOROQUINOLONES, GRAM-negative anaerobic bacteria, RESPIRATORY infections, PENICILLIN, MULTIDRUG resistance, DESCRIPTIVE statistics, DRUG resistance in microorganisms, PSEUDOMONAS, URINALYSIS, IMIPENEM, PHENOTYPES, MICROBIAL sensitivity tests, PHARMACODYNAMICS
Abstract

Background Multidrug-resistant (MDR) bacteria are frequently defined using the criteria established by Magiorakos et al [Clin Microbiol Infect 2012;18:268–81]. Difficult-to-treat resistance (DTR) [Kadri et al, Clin Infect Dis 2018;67:1803–14] is a novel approach to defining resistance in gram-negative bacilli focusing on treatment-limiting resistance to first-line agents (all β-lactams and fluoroquinolones). Methods Clinical and Laboratory Standards Institute–defined broth microdilution minimum inhibitory concentrations (MICs) were determined for imipenem/relebactam, ceftolozane/tazobactam, and comparators against respiratory, intraabdominal, and urinary isolates of Enterobacterales (n = 10 516) and Pseudomonas aeruginosa (n = 2732) collected in 26 US hospitals in 2015–2017. Results Among all Enterobacterales , 1.0% of isolates were DTR and 15.6% were MDR; 8.4% of P. aeruginosa isolates were DTR and 32.4% were MDR. MDR rates for Enterobacterales and DTR and MDR rates for P. aeruginosa were significantly higher (P < .05) in isolates collected in intensive care units (ICUs) than in non-ICUs and in respiratory tract isolates than in intraabdominal or urinary tract isolates. In addition, 82.4% of DTR and 92.1% of MDR Enterobacterales and 62.2% of DTR and 82.2% of MDR P. aeruginosa were imipenem/relebactam-susceptible, and 1.5% of DTR and 65.8% of MDR Enterobacterales and 67.5% of DTR and 84.0% of MDR P. aeruginosa were ceftolozane/tazobactam-susceptible. Conclusions MDR phenotypes defined using the Magiorakos criteria may overcall treatment-limiting resistance in gram-negative bacilli. In the US, DTR Enterobacterales were infrequent, while MDR Enterobacterales isolates and DTR and MDR P. aeruginosa were common. Imipenem/relebactam (Enterobacterales , P. aeruginosa) and ceftolozane/tazobactam (P. aeruginosa) retained in vitro activity against most DTR and MDR isolates. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results